Q12 cáncer diferenciado de tiroides (CDT): estimulación de la TSH endógena con múltiples dosis de TRH y su tratamiento con 131I: experiencia de 3 años / Differentiated thyroid carcinoma: endogenous TSH stimulation by multiple dosage of TRH and treatment with 131I

La búsqueda un método alternativo a la rh-TSH para estimular el aumento de la TSH sérica previo al tratamiento con 131I en pacientes con CDT operados con reducción del tiempo del hipotiroidismo pre ablativo fue el propósito del trabajo que iniciamos en el año 2001 en el Paraguay utilizando múltiples dosis de TRH para estimular la TSH endógena de los pacientes para luego lograr la ablación del remanente tiroideo con 131I. Se conoce que la inyección de una dosis única de 200µU de TRH por vía EV logra el aumento de la TSH endógena en los pacientes con carcinoma diferenciado de tiroides logrando elevar la TSH entre 30 - 35 mUI/L al final de la primera hora , sin embargo, no se cuentan con datos estadísticos de los efectos de múltiples inyecciones de TRH aplicadas por vía EV o por vía IM en los pacientes operados de tiroides por CDT previamente a la ablación con 131I. Material y Método: Desde el 2001al 2007 doscientos pacientes operados por CDT fueron estudiados por este método en el Centro de Diagnostico y Tratamiento Nuclear (CEDIN), 120 correspondieron a cáncer papilar y 80 a cáncer folicular. Ciento ochenta no presentaron metástasis a distancia y 20 presentaron metástasis en cuello, tórax, pelvis y columna dorsal. Tiroidectomía total se realizó en 120 y lobectomía total e itsmectomía más hemilobectomía del lado contra lateral en 80. Todos fueron tratados con dosis ablativas (100 mCi (3.700 mBq) de 131I excepto aquellos con metástasis que recibieron 150 mCi (5.500 mBq) previa estimulación con TRH por vía EV en dos dosis diarias por dos días con previa suspensión de L-tiroxina por 25 días antes del tratamiento reemplazándola por triyodotironina 25 mcg/día por 15 días tras lo cual también fue suspendida 10 días antes de la estimulación con TRH y el tratamiento con 131I. Dos pacientes con metástasis recibieron otra dosis extra de 150 mCi (5.550 MBq) 6 meses después...

The search of an alternative method to the rh-TSH to stimulate endogenous rising of TSH previous to thyroid ablation with 131I in patients with CDT operated. The purpose of the work began in 2001 in Paraguay using multiple dose of TRH IV (200µU of TRH Threlea® Argentina) to stimulate the own TSH of patients previous to 131I ablation. It is known that the injection of an unique dose of 200µU of TRH IV achieves the increasing of the endogenous TSH in patients with differentiated thyroid carcinoma up to 30 - 35 mUI/L at the end of the first hour, however, there is not statistical data of the effects of multiple injections of TRH applied IV or IM in operated patients of DTC previous to the ablation with 131I. Since 2001-2007, two hundred patients operated for DTC were studied by this method, 120 were papillary cancer and 80 follicular cancer. One hundred eighty did not have distance metastasis and 20 presented metastasis in thorax, pelvis and dorsal spine. Total thyroidectomy was carried out in 120 and total lobectomy with itsmectomy plus hemilobectomy of the other lobe in 80. All were treated with ablative dose of 100 mCi (3.700 mBq) of 131I, except those with metastasis which receive 150 mCi (5.500 mBq) with the previous stimulation with TRH IV with two daily dose for three days with previous suspension of L-tiroxine for 25 days and replaced by triyodotiroxine 25 mcg/d for 15 days with suspension 10 days before the stimulation with TRH and treatment with 131I. Two patients with metastasis received another extra dose of 150 mCi (5.550 MBq) 6 months later. One presented uptake in thyroid bed one year after the ablation received a new ablative dose of 100 mCi (3.700 mBq) of 131I. All the patients were interned and isolated by 48 hours. Twenty feminine patients had later pregnancies in 1-3 years after their ablative dose with healthy products. TSH was measured during the stimulation with TRH in all patients...

Cinco diferentes tipos de imágenes gammagráficas tiroideas en pacientes con enfermedad de Graves tratados con 131I en el Paraguay / Five different gammagraphic images of thyroid gland in patients with Grave’s disease treated with 131I in Paraguay

Thyroid disease is frequent in Paraguay, a country with a prevalence of goiter 48,6 percent in general population located in the center of South America. Grave’s disease constitutes the most common thyroid hyperfunction observed whose treatment can be carried out with medication (propiltiouracil, metimazol, etc.), surgery or iodine 131(131I) We analyzed 70 patients this type of hyperthyroidism treated with the 131I, in its clinical aspect pre and post treatment, ultrasound and nuclear scan findings of the gland thyroid, the hormonal respond Ft4, T3, TSH, thyroid antibodies TPOab, TGab, TRab. Besides the diffuse classic image observed in the thyroid scan and by ultrasonography of the gland, in Grave’s disease, 4 types of images were identified with nodules (multinodular, hot nodule, cold nodule and miliar). The group with diffuse increase in size form was the most numerous (50 percent) continued by the variety multinodular (30 percent), Marin-Lenhart’s Sx (hot nodule) 14 percent, miliary 3 percent, and cold nodule 3 percent. Three months after the treatment with the radioiodine was observed the decrease of the size and thyroid volume in 68 percent of the patients, thyroid uptake with 131I diminished in 75 percent. All patients had an increase of weight of 20 percent and 87 percent of then were feminine. The signs and symptoms were normalized in 88,5 percent of the patients. The levels of FT4 were normalized in 73, 8 percent, T3 in 66 percent, TSH in 47,7 percent, TPOab in 83 percent, TGab in 90 percent, and TRab in 84 percent. A received a single dose of 131I was used it in 93 percent of the patient The cost of the 131I in the Clinic Hospital was half of the cost of the surgery, and at private level the fourth part but cheap.

Recurrencia de feocromocitoma en escolar de 11 años diagnosticado por I-131 MIBG / Recurrence of pheocromocytoma in 11 years old school child, diagnosed by I-131 MIBG

Pheocromocytoma is a paraganglioma with an incidence of arterial hypertension approximately of 1 percent ,but its diagnosis has several important issues from the clinical point of view. 1-The tumor resection frecuently cure the hypertension. 2.-Its manifestations might simulates other diseases like carcinoid Sx, hypertiroidism,etc. 3.-It is a familiar disease transmitted by an autosomic dominant way. It is 10 percent ilateral, 10 percent extraadrenal, 10 percent occur in children and 10 percent are malignant. We present a case of pheocromocytoma recurrency in a young girl,11 y.o. operated 8 months before, at the Clinical Hospital, National University of Paraguay, School of Medicine for a right suprarrenal gland pheocromocytoma of 2cms of diameter, who consults the Pediatryc Department for arterial hypertension and cefalea. She also had a Von Hippel Sx and Glaucoma. Nuclear Medicine is a non invasive method that use the I-131M ethayodobencylguanidine(MIBG-I-131) with high accuracy to diagnose and treat both neuroblastoma and pheocromocytoma I-131 MIBG is the gold standard for the diagnosis of both entities with a sensitivity between 94-100 percent and specificity of 100 percent being the best method to evaluate these diseases in the pre and post operatory